Insilico Medicine and SK Biopharmaceuticals have entered a significant collaboration worth up to $2.5 billion aimed at advancing AI-driven drug discovery for neuroimmune disorders.
The partnership, announced at the BIO 2026 International Convention, will leverage Insilico's Pharma.AI platform to identify drug targets, optimize molecules, and enhance preclinical drug discovery specifically for conditions affecting the central nervous system (CNS). This initiative addresses critical unmet medical needs in neuroinflammatory, neurodegenerative, and rare neurological disorders, which often face low success rates in clinical trials.
As part of the agreement, Insilico will receive up to $18 million in initial and milestone payments, with the potential for the total deal value to surpass $2.5 billion through various developmental and sales-related milestones. SK Biopharmaceuticals will take the lead on late-stage development and commercialization, drawing on its established expertise in CNS therapies.
This collaboration underscores the growing importance of AI in drug discovery and the potential for partnerships to drive innovation in the life sciences sector. By combining Insilico's advanced AI capabilities with SK Biopharmaceuticals' clinical experience, the alliance aims to significantly reduce the typical drug discovery timeline from several years to a mere 12–18 months, thereby accelerating the development of new therapeutic options for challenging CNS disorders.